Komori
KYORIN Pharmaceutical (4569) · PolicyRestated

Change to the Straight-Line Method of Depreciating Property, Plant and Equipment

First written in FY2019-Q2. 2 of 3 entries say "Restated". Latest entry: FY2019.

3entries
2years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2019-Q2 – FY20192018: 120182019: 22019
Same theme, other companies
Change in Depreciation Method Based on Actual Usage at Domestic Consolidated CompaniesA theme 20 companies write about · 0 as a headwind · 11 as a tailwind

15 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 20 companies compared. The sentences above are computed from all 20.
Full recordFilings, disclosures and news, newest first
  1. FY2019RestatedAnnual report

    「As a result of this change, compared with the previous method, depreciation expenses for the current consolidated fiscal year decreased by ¥697 million, operating income increased by ¥664 million, and ordinary income and profit before income taxes for the fiscal year each increased by ¥663 million.」

    The company continues to apply the change to the straight-line depreciation method and has disclosed its impact on profit for the fiscal year.
  2. FY2019-Q3RestatedAnnual report

    「As a result of this change, compared with the previous method, depreciation expenses for the nine-month period ended in the third quarter decreased by ¥498 million, while operating income and ordinary income and profit before income taxes for the quarter each increased by ¥469 million.」

    The company continues to apply the change to the straight-line depreciation method and has disclosed its impact on profit for the nine-month period ended in the third quarter.
  3. FY2019-Q2First statedAnnual report

    「From the first quarter of the consolidated fiscal year, the Company and its domestic consolidated subsidiaries also changed to the straight-line method. Compared with the previous method, depreciation expense for the first six months of the consolidated fiscal year decreased by ¥327 million, while operating profit increased by ¥295 million and ordinary profit and profit before income taxes increased by ¥295 million each.」

    The depreciation method for property, plant and equipment was changed from the declining-balance method to the straight-line method in anticipation of more stable and level utilization of production and R&D facilities.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for KYORIN Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.